H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals. Lu 02-750 is a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated very convincing effects as compared to conventional treatments. Expectations are that the compound can offer Parkinson's patients a new and higher level of disease control.
"Focus at Lundbeck Research is to discover new innovative treatments that address unmet needs and offer clear benefits to the patients and we believe that Lu 02-750 has the potential to improve the treatment and life quality of patients suffering from Parkinson's disease", says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck and continues: "Lundbeck is actively pursuing external technologies and collaborations and Lu 02-750 has been discovered in close collaboration with Professor Håkan Wikström, Groningen University and Axon Biochemicals B.V."
About Parkinson's disease
Parkinson's disease is an age-related degenerative disorder of the brain. Symptoms can include tremor, stiffness, slowness of movement and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60.
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.